Coya Therapeutics (COYA) Common Equity (2021 - 2026)
Coya Therapeutics (COYA) posted Common Equity of $49.0 million for Q1 2026, up 13.81% sequentially from $43.0 million in Q4 2025, and up 46.75% YoY from $33.4 million in Q1 2025.
Coya Therapeutics (COYA) Common Equity (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Common Equity for 6 years, with the latest figure at $49.0 million in Q1 2026.
- Quarterly Common Equity rose 46.75% year-over-year to $49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.0 million (up 46.75% YoY) and the FY2025 annual result came in at $43.0 million, up 8.72% from the prior year.
- Common Equity rose to $49.0 million in Q1 2026 per COYA's latest filing, from $43.0 million in the prior quarter.
- Over five years, Common Equity peaked at $49.0 million in Q1 2026 and troughed at -$8.4 million in Q4 2022.
- A 5-year average of $22.5 million and a median of $28.3 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity sank 330.36% in 2022, then jumped 1042.04% in 2023.
- Over 5 years, Common Equity stood at -$8.4 million in 2022, then soared by 524.56% to $35.6 million in 2023, then climbed by 11.06% to $39.6 million in 2024, then climbed by 8.72% to $43.0 million in 2025, then gained by 13.81% to $49.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $49.0 million, $43.0 million, and $27.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.79 Bn |
| 10 | Coya Therapeutics | 114.94 Mn | 71.74 Mn | - | 43.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.28 Mn |
| Mar 31, 2026 | 48.97 Mn |
| Dec 31, 2025 | 43.03 Mn |
| Sep 30, 2025 | 27.28 Mn |
| Jun 30, 2025 | 28.31 Mn |
| Mar 31, 2025 | 33.37 Mn |
| Dec 31, 2024 | 39.58 Mn |
| Sep 30, 2024 | 32.01 Mn |
| Jun 30, 2024 | 35.26 Mn |
| Mar 31, 2024 | 32.39 Mn |
| Dec 31, 2023 | 35.64 Mn |
| Sep 30, 2023 | 10.09 Mn |
| Jun 30, 2023 | 13.25 Mn |
| Mar 31, 2023 | 16.15 Mn |
| Dec 31, 2022 | -8.39 Mn |
| Sep 30, 2022 | -5.36 Mn |
| Jun 30, 2022 | -1.41 Mn |
| Mar 31, 2022 | 1.96 Mn |
| Dec 31, 2021 | 3.64 Mn |